Open AccessImpact of somatic mutations on prognosis in resected non‐small‐cell lung cancer: The Japan Molecular Epidemiology for lung cancer study
Author(s) -
Tamiya Akihiro,
Koh Yasuhiro,
Isa Shunichi,
Kubo Akihito,
Ando Masahiko,
Saka Hideo,
Yoshimoto Naoki,
Takeo Sadanori,
Adachi Hirofumi,
Tagawa Tsutomu,
Kawashima Osamu,
Yamashita Motohiro,
Kataoka Kazuhiko,
Takenoyama Mitsuhiro,
Takeuchi Yukiyasu,
Watanabe Katsuya,
Matsumura Akihide,
Kawaguchi Tomoya
Publication year - 2020
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.2897
Subject(s) - medicine , lung cancer , kras , epidemiology , proportional hazards model , oncology , hazard ratio , gastroenterology , cancer , stage (stratigraphy) , adenocarcinoma , colorectal cancer , confidence interval , biology , paleontology
Background To report the follow up data and clinical outcomes of the JME study (UMIN 8177), a prospective, multicenter, molecular epidemiology examination of 876 surgically resected non‐small‐cell lung cancer (NSCLC) cases, and the impact of somatic mutations (72 cancer‐associated genes) on recurrence‐free survival (RFS) and overall survival (OS). Methods Patients were enrolled between July 2012 and December 2013, with follow up to 30th November 2017. A Cox proportional hazards model was used to assess the impact of gene mutations on RFS and OS, considering sex, smoking history, age, stage, histology, EGFR , KRAS , TP53 , and number of coexisting mutations. Results Of 876 patients, 172 had ≥2 somatic mutations. Median follow‐up was 48.4 months. On multivariate analysis, number of coexisting mutations (≥2 vs 0 or 1, HR = 2.012, 95% CI: 1.488‐2.695), age (≥70 vs <70 years, HR = 1.583, 95% CI: 1.229‐2.049), gender (male vs female, HR = 1.503, 95% CI: 1.045‐2.170) and pathological stage (II vs I, HR = 3.386, 95% CI: 2.447‐4.646; ≥III vs I, HR = 6.307, 95% CI: 4.680‐8.476) were significantly associated with RFS, while EGFR mutation (yes vs no, HR = 0.482, 95% CI: 0.309‐0.736), number of coexisting mutations (≥2 vs 0 or 1, HR = 1.695, 95% CI: 1.143‐2.467), age (≥70 vs <70 years, HR = 1.932, 95% CI: 1.385‐2.726), and pathological stage (II vs I, HR = 2.209, 95% CI: 1.431‐3.347; ≥III vs I, HR = 5.286, 95% CI: 3.682‐7.566) were also significant for OS. Conclusion A smaller number of coexisting mutations, earlier stage, and younger age were associated with longer RFS and OS, while EGFR mutations were significantly associated with improved OS.